Morgan Stanley analyst Kristine Liwag maintains Lockheed Martin (NYSE:LMT) with a Overweight and raises the price target from $521 to $525.
VBL Therapeutics Announces Workforce Reduction
VBL Therapeutics (NASDAQ:VBLT), a biotechnology company developing targeted medicines for cancer and immune-inflammatory diseases, today announced an organizational streamlining designed to reduce operating expenses and